Amarin reported $634.08M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amarin USD 634.08M 9.72M Sep/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
DBV Technologies USD 215.4M 7.8M Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Heron Therapeutics USD 252.26M 6.05M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026